<DOC>
	<DOCNO>NCT00660582</DOCNO>
	<brief_summary>The Nordic FLOX-regime consist combination bolus 5-FU , leukovorin oxaliplatin ( Eloxatin® ) . Cetuximab ( Erbitux® ) antibody epidermal growth factor receptor ( EGFR ) . The combination FLOX weekly Erbitux investigate Nordic VII study 571 patient randomize FLOX ( regime A ) FLOX + Erbitux ( regime B C ) . Effect-data yet publish combination well tolerate , study show Erbitux administer chemotherapy seem efficient chemotherapy alone . The main purpose study investigate effect FLOX Erbitux give every second week first line treatment patient metastatic colorectal cancer K-RAS wildtype tumor . The late accessible data regard treatment towards EGFR K-RAS mutation show patient K-RAS wildtype respond well treatment patient K-RAS mutation .</brief_summary>
	<brief_title>FLOX + Cetuximab ( Erbitux® ) Patients With Metastatic Colorectal Cancer Wild Type K-RAS Tumor</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Histology stag disease : Histological proven adenocarcinoma colon rectum At least one measurable metastatic lesion accord RECIST criterion If one metastatic lesion , histology mandatory Mutation level : Tumor tissue ( primary metastasis ) typological classify KRAS wildtype codon 12 13 exon 1 realtime PCR General condition : Age &gt; 18 &lt; 75 year WHO performance status ≤ 2 ; life expectancy 3 month Adequate haematological function : ( Hb ≥ 6.2 μmol/d , ANC ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L ) Adequate renal hepatic function : total bilirubin ≤ 1.5 upper normal limit , creatinine ≤ 1.25 × upper normal limit , ALAT ≤ 3 x upper normal limit , ≤ 5 x upper normal limit case liver metastasis Written inform consent prior randomisation must obtain document accord local regulatory requirement Other : Fertile patient must use adequate contraceptive Prior therapy : Prior chemotherapy advanced/metastatic disease Adjuvant chemotherapy must end &gt; 6 month inclusion Prior treatment Eloxatin Prior treatment Erbitux treatment EGFR Prior current history : Current indication resection curative intent Evidence CNS metastasis Current infection , unresolved bowel obstruction subobstruction , uncontrolled Crohn 's disease ulcerative colitis Current history chronic diarrhea Peripheral neuropathy Other serious illness medical condition ( include contraindication 5 FU e.g . : angor , myocardial infarction within 6 month , contraindication monoclonal antibody ) Past concurrent history malignant neoplasm colorectal adenocarcinoma within past five year , except curatively treat non melanoma skin cancer situ carcinoma cervix Concomitant treatment : Concomitant ( within 4 week randomisation ) administration experimental drug investigation Concurrent treatment anticancer therapy Other : Pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Erbitux</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Flox</keyword>
	<keyword>Fluorouracil + folinic acid</keyword>
	<keyword>K-RAS</keyword>
</DOC>